Compare PNBK & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNBK | CYBN |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.5M | 147.4M |
| IPO Year | N/A | N/A |
| Metric | PNBK | CYBN |
|---|---|---|
| Price | $1.29 | $5.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $71.25 |
| AVG Volume (30 Days) | 237.6K | ★ 716.3K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $4.81 |
| 52 Week High | $7.47 | $11.08 |
| Indicator | PNBK | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 46.45 |
| Support Level | $1.08 | $5.52 |
| Resistance Level | $1.44 | $6.23 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 62.82 | 42.65 |
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.